Stockscreener 앱 받기
1.35
0.75%
0.01
전일 마감가:
$1.34
열려 있는:
$1.36
하루 거래량:
392.73K
Relative Volume:
1.41
시가총액:
$16.09M
수익:
$2.47M
순이익/손실:
$-24.73M
주가수익비율:
-0.3204
EPS:
-4.213
순현금흐름:
$-20.36M
1주 성능:
-3.57%
1개월 성능:
-2.88%
6개월 성능:
-79.73%
1년 성능:
-90.07%
1일 변동 폭
$1.34
$1.53
1주일 범위
$1.24
$1.53
52주 변동 폭
$1.17
$16.00
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
1.35 | 16.09M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
527.05 | 195.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 140.88B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.57 | 44.46B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.95 | 38.66B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
134.29 | 37.93B | 7.23B | 1.41B | 1.09B | 4.979 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRX (VNRX) Registration filing Summary - Quartr
VNRX Announces Sale of 3.31 Million Shares by Selling Stockholders - GuruFocus
VolitionRx (NYSE: VNRX) files to register 3.3M Lind-linked shares for resale - Stock Titan
Maxim Group Maintains VolitionRX(VNRX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
VolitionRx Ltd explores blood-based cancer diagnostics as investors watch VNRX - ad-hoc-news.de
VolitionRx releases lung cancer prognostic study data - Investing.com
VolitionRx releases lung cancer prognostic study data By Investing.com - Investing.com Australia
VolitionRx’s lung cancer test could help doctors predict outcomes - Stock Titan
VolitionRx prices $4.6 million public offering at $1.55 per share By Investing.com - Investing.com UK
VolitionRX Ltd (VNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VolitionRX Ltd Actuals & Estimates (AMEX:VNRX) - TradingView
VolitionRX Ltd (VNRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VolitionRX Ltd (VNRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VNRX Forecast — Price Target — Prediction for 2027 - TradingView
VolitionRX Ltd (VNRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Sysmex (TSE:6869)'s Nu.Q NETs Collaboration With VolitionRx Means For Shareholders - simplywall.st
VolitionRX Ltd (VNRX) Institutional Confidence - TradingKey
VOLITIONRX ANNOUNCES PRICING OF $4.6 MILLION PUBLIC OFFERING - Moomoo
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VNRX Reinstated by Maxim Group -- Price Target Announced at $4.0 - GuruFocus
VolitionRx Limited 8-K Filing: Key Corporate Details and SEC Registration for June 2026 - Minichart
VolitionRx (NYSE: VNRX) issues stock to Lind for note repayments - Stock Titan
VolitionRx (VNRX) Receives Buy Rating with $4 Price Target from Maxim - GuruFocus
VolitionRX Ltd (VNRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VolitionRX Ltd (VNRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VolitionRX Ltd (VNRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VolitionRx Limited (VNRX) Partners with Sysmex to Enhance Diagno - GuruFocus
Sysmex (TSE:6869) Stock Could Be 17.8% Undervalued After VolitionRx Collaboration - simplywall.st
VolitionRx (VNRX) Forms Partnership with Sysmex for Assay Optimi - GuruFocus
VolitionRx partners with Sysmex on diagnostic test development By Investing.com - Investing.com Nigeria
VolitionRx partners with Sysmex on diagnostic test development - Investing.com
VolitionRx partners with Sysmex to optimize NETs test for sepsis and other diseases - Stock Titan
VolitionRx Ltd Stock (US92852X1037): Quarterly earnings keep early-detection biotech in focus - Ad-hoc-news.de
VolitionRx Enters Securities Purchase Agreement With Investors to Raise Capital - TradingView
VolitionRx (NYSE: VNRX) prices $4.6M stock offering with $2.3M warrant upside - Stock Titan
VolitionRx (NYSE: VNRX) to Offer 2.96M Shares and 1.48M Warrants - Stock Titan
VolitionRx stock tumbles on $4.6M offering priced at discount By Investing.com - Investing.com Nigeria
VolitionRx prices $4.6 million public offering at $1.55 per share - Investing.com
VolitionRx Announces Pricing of $4.6 Million Public Offering - marketscreener.com
Epigenetics firm VolitionRx prices $4.6M deal with $2.3M in potential warrant proceeds - Stock Titan
VolitionRx (VNRX) files shelf prospectus for stock, detachable warrants - Stock Titan
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com
VNRX Technical Analysis & Stock Price Forecast - Intellectia AI
New Ebola triage blood test: VolitionRx seeks partners for outbreak zones - Stock Titan
VolitionRx (NYSE: VNRX) seeks approval to cut authorized shares and add 2026 stock plan - Stock Titan
Benchmark reiterates Hold on VolitionRX stock amid milestones By Investing.com - Investing.com South Africa
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.63%
자본화:
|
볼륨(24시간):